A randomised trial of a contraceptive vaginal ring in women at risk of HIV infection in Rwanda: Safety of intermittent and continuous use

Abstract

BackgroundContraceptive vaginal rings could play a role in expanding the contraceptive method mix and in preparing communities for the introduction of HIV prevention and multipurpose rings.MethodsWe conducted an open label single-centre randomised clinical trial of intermittent versus continuous use of NuvaRing® in Kigali, Rwanda, in 2013–2014. We randomised 120 HIV-negative women 1:1 to intermittent use (three rings with a ring-free week in between rings) or continuous use (four rings without ring-free weeks). Women underwent an interview, counselling, and a speculum examination, and were tested for pregnancy, bacterial vaginosis (BV) by Nugent scoring, yeasts and trichomonads on wet mount, and sexually transmitted infections.FindingsOnly one woman withdrew early. Deliberate ring removals were rare, but spontaneous ring expulsions occurred during 14% of ring use periods. There were no incident pregnancies, serious adverse events, serious social harms, or early discontinuations for safety reasons. Systemic side effects were uncommon, and local side effects were not significantly differently distributed between groups except for lower abdominal pain (P = 0.013). The incidence of vaginal yeasts during ring use was high: 22% of intermittent users and 27% of continuous users had incident vaginal yeasts at one or multiple ring removal visits (P = 0.666), and symptomatic vaginal yeast cases were more common in the continuous than intermittent users (P = 0.031). In contrast, mean Nugent scores improved over time in both groups.ConclusionsIntermittent and continuous NuvaRing® use were safe in Rwandan women and improved Nugent scores over time. However, attention should be paid to ring expulsions and to a potential increased risk of vaginal candidiasis.

Hormonal contraception alters vaginal microbiota and cytokines in South African adolescents in a randomized trial

“…The CCVR group also had a higher number of Candida infections compared to the other groups. In Rwandan women, the percentage of women with vaginal yeast increased from 5 to 22% after CCVR initiation 46 , and in vitro data corroborate this 47 , further supporting this possibility. Many different vaginal rings are currently in clinical trials, and our findings may be specific to NuvaRing®.…”

Combined oral contraceptive pill-exposure alone does not reduce the risk of bacterial vaginosis recurrence in a pilot randomised controlled trial

“…We undertook this pilot to determine whether hormonal contraception following antibiotic therapy reduced BV-recurrence compared to antibiotic therapy alone and to assess the feasibility of the intervention. Women using hormonal contraception have a reduction in BV in a number of observational studies 13,15 , and a recent NuvaRing® trial in 120 women showed improved mean Nugent scores over 3-months 16 . A favourable effect of combined oestrogen-progesterone contraception on the vaginal microbiota may be explained by several mechanisms.…”

Hormonal contraception and HIV acquisition among women: an updated systematic review

“…We screened 769 abstracts and 17 full-text reports (online supplementary figure 1). We excluded 13 full-text reports – four reported on data already included in the 2016 review, six were letters or conference abstracts, and three had an irrelevant exposure, outcome or comparison group 12–24. From a conference abstract,13 we identified an additional 'in press' study, which has now been published 25.…”